TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36450540
Drug: SeQuent Please
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeQuent Please paclitaxel-coated balloon (3 μg/mm2)
Study: 36450540
Drug: Agent in
Normalized name: Plant agent insecticide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agent in ISR substudy
Study: 34854315
Drug: Appropriate ICD
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Appropriate ICD therapy
Study: 33162198
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group with identifiable victim message
Study: 33162198
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group with exponential transmission message
Study: 36174257
Drug: Multi-function swing
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multi-function swing suspension training program (MFSST)
Study: 32325419
Drug: Tecemotide (L-BLP25)
Normalized name: L
DrugBank: Tecemotide (DB12568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecemotide (L-BLP25) added to standard-of-care treatment
Study: 32325419
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment alone
Study: 33909194
Drug: Monthly pharmaceutical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly pharmaceutical care follow-up for 6 months
Study: 33947355
Drug: Prednisolone 1
Normalized name: prednisolone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 1 mg/kg/day (maximum 50 mg/day) for 10 days
Study: 33947355
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for oral intake once daily for 10 days
Study: 34044977
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HVE and intraoral suction device
Study: 35322001
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor combined with bevacizumab
Study: 35322001
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with paclitaxel chemotherapy
Study: 35322001
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor combined with bevacizumab (dMMR patients)
Study: 35322001
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor combined with bevacizumab (PMMR patients)
Study: 35322001
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with paclitaxel chemotherapy (dMMR patients)
Study: 35322001
Drug: Bevacizumab combined
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab combined with paclitaxel chemotherapy (PMMR patients)
Study: 32488754
Drug: Soy isoflavones
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavones (100 mg daily for 8 weeks)
Study: 35525238
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) for quitting smoking and weight gain prevention
Study: 35525238
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) plus contingency management (CM)
Study: 34284567
Drug: High-dose pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pulsed methylprednisolone
Study: 35460734
Drug: Online intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online intervention adjunct to treatment-as-usual (TAU)
Study: 35565823
Drug: Catechin group
Normalized name: catechin
DrugBank: Cianidanol (DB14086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Catechin group (490 mg catechin, 0.14%, containing 59% epi-type catechin, n = 55)
Study: 35565823
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (0 mg catechin, n = 54)
Study: 34284808
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg BID (with initial dose titration on days 1–6)
Study: 35793101
Drug: 10-mg balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg balovaptan adult-equivalent dose
Study: 35793101
Drug: 4-mg balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg balovaptan adult-equivalent dose
Study: 34414642
Drug: TXA intradermal-microinjection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA intradermal-microinjection every 2 weeks for 3 months
Study: 36408238
Drug: Jiaotaiwan (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiaotaiwan (2-g JTW granules, b.i.d. for 7 days)
Study: 36408238
Drug: Placebo (2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2-g placebo granules, b.i.d. for 7 days)
Study: 36286633
Drug: UDCA Ursofalk
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA Ursofalk (Germany) at a dose of 10 mg/kg for at least 6 months
Study: 36286633
Drug: UDCA (another
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (another manufacturer) at a dose of 10 mg/kg for at least 6 months
Study: 35771692
Drug: Intervention related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention related to lifestyle change for prediabetes; specific details on dosage and duration not available.
Study: 35597718
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patch applied 2–8 hours before puncture.
Study: 35597718
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (only covering material).
Study: 32318963
Drug: Low-dose DOACs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DOACs (edoxaban or rivaroxaban)
Study: 32318963
Drug: Normal-dose DOACs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose DOACs (edoxaban or rivaroxaban)
Study: 32318963
Drug: Rivaroxaban and
Normalized name: rivaroxaban and acetylsalicylic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban and Warfarin (for hemopericardium)
Study: 33336698
Drug: DOR/3TC/TDF (Doravirine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOR/3TC/TDF (Doravirine 100 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg)
Study: 33336698
Drug: EFV/FTC/TDF (Efavirenz
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFV/FTC/TDF (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil Fumarate 300 mg)
Study: 32479166
Drug: Rituximab infusion
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab infusion every 6 months for 18 months (4 infusions)
Study: 32479166
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion every 6 months for 18 months (4 infusions)
Study: 32663852
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin + clavulanic acid 1 hour before surgery and 1 g amoxicillin + clavulanic acid twice a day for 5 days after surgery
Study: 32663852
Drug: No perioperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No perioperative antibiotic therapy
Study: 34378860
Drug: Overall implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall implants
Study: 35405099
Drug: ACEI/ARB discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB discontinuation in mild disease
Study: 35405099
Drug: ACEI/ARB discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI/ARB discontinuation in moderate disease
Study: 34333575
Drug: Condoms and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Condoms and the pill
Study: 32844723
Drug: RUC-4 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUC-4 at 0.05 mg/kg
Study: 32844723
Drug: RUC-4 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUC-4 at 0.075 mg/kg
Study: 32844723
Drug: RUC-4 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RUC-4 at 0.04 mg/kg
Study: 34785365
Drug: 10Hz M1‐rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10Hz M1‐rTMS over 2 weeks (real treatment)
Study: 34785365
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (sham control)
Study: 32615951
Drug: Crowdsourcing materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crowdsourcing materials to promote HCV testing (administered once a week for two weeks)
Study: 33826614
Drug: Alternate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate treatment arm
Study: 34329577
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide (5 g/m2), carboplatin (AUC 5), and etoposide (100 mg/m2) for two 21-day cycles.
Study: 34329577
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide, carboplatin, and etoposide.
Study: 33000415
Drug: Tongyan Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongyan Spray (通咽喷雾剂) applied to the pharynx 30 min before examination
Study: 33953542
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg lobeglitazone sulfate
Study: 33953542
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 25 mg empagliflozin and 0.5 mg lobeglitazone sulfate
Study: 32988385
Drug: Mirtazapine (MTZ)
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine (MTZ) 10 mg/kg for 30 days in HET mice
Study: 35417538
Drug: BCG +
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG + Oral Polio Vaccine (OPV) immediately
Study: 35417538
Drug: BCG +
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG + Oral Polio Vaccine (OPV) at hospital discharge
Study: 34184474
Drug: Ampasse (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampasse (5 mg/ml, 5 ml intravenously bolus slowly for 15 days)
Study: 34184474
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride, 5 ml)
Study: 35596578
Drug: THC +
Normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC + CBD (8 mg THC + 10 mg CBD)
Study: 35596578
Drug: CBD (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (600 mg, oral)
Study: 33583165
Drug: Duloxetine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine + Okada Purifying Therapy (Group II)
Study: 34165151
Drug: CVRS2 design
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CVRS2 design treatment
Study: 33345876
Drug: Dapagliflozin-Metformin
Normalized name: dapagliflozin-metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin-Metformin
Study: 33096362
Drug: Medication Safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Safety Enhancement (MSE) simulation program with integrated technology
Study: 35660539
Drug: Pharmacogenomic testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic testing for relevant antihypertensive medications
Study: 33020052
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100 μg or 4,000 units daily)
Study: 35022783
Drug: suvorexant 10-20
Normalized name: suvorexant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant 10-20 mg nightly for 4 weeks
Study: 33493011
Drug: Low-Dose Aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Dose Aspirin (LDA) for 5 of 7 days per week
Study: 33493011
Drug: Postconception initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Postconception initiation of LDA therapy
Study: 34320428
Drug: 75 J.cm−2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 J.cm−2 LED, 600 μmol.L−1 curcumin
Study: 34320428
Drug: 600 μmol.L−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μmol.L−1 curcumin plus 17% EDTA
Study: 34320428
Drug: 600 μmol.L−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μmol.L−1 curcumin plus 18% HEBP
Study: 34320428
Drug: 600 μmol.L−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μmol.L−1 curcumin plus 75 J.cm−2 LED
Study: 34320428
Drug: 600 μmol.L−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μmol.L−1 curcumin plus 17% EDTA and 75 J.cm−2 LED
Study: 34320428
Drug: 600 μmol.L−1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 μmol.L−1 curcumin plus 18% HEBP and 75 J.cm−2 LED
Study: 34529859
Drug: LED treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED treatment (590, 630, and 850 nm with two tested irradiances each)
Study: 32176657
Drug: Individually Tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT) combined with standard medical treatment
Study: 32176657
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment plus being on waitlist to ICBT (CONTROL)
Study: 32176657
Drug: Individually Tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT)
Study: 35412032
Drug: Budesonide orodispersible
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide orodispersible tablet (BOT) 1 mg BID for 6 weeks
Study: 33933921
Drug: Screening, notifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening, notifying the PCP, and providing enhanced depression treatment
Study: 33589408
Drug: MitraClip plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip plus maximally tolerated guideline‐directed medical therapy (GDMT)
Study: 35354299
Drug: Rigorous preclinical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rigorous preclinical assessment with treatment masking, randomization, and blinded assessment.
Study: 32428843
Drug: Aquatic exercise
Normalized name: Mentha aquatica leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic exercise twice a week (2x/w)
Study: 34896280
Drug: Mindfulness-based music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based music therapy intervention (4 sessions over 12 weeks)
Study: 34090515
Drug: Pediatric integrative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric integrative manual therapy (PIMT) plus caregiver education program
Study: 33907210
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) applied with a GaAlAs laser (wavelength=810 nm) at pre-determined points in the masseter muscle (6 J/cm2, 3 regions, 60 s) or TMJ region (6 J/cm2, 5 points, 30 s) for 7 consecutive days.
Study: 33907210
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 7 consecutive days.
Study: 33984725
Drug: Postoperative dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative dose-dense adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy
Study: 32562573
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg daily low-dose aspirin
Study: 33686753
Drug: Abemaciclib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib + endocrine therapy (ET) in MONARCH 2
Study: 33686753
Drug: Abemaciclib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib + endocrine therapy (ET) in MONARCH 3
Study: 33896276
Drug: Standard-of-care therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR)
Study: 33418367
Drug: Bio-psycho-social treatment
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-psycho-social treatment programme (6-7 months)
Study: 34985366
Drug: rPMS (20Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPMS (20Hz and 2400 pulses to triceps brachii and extensor digitorum muscles daily for two weeks in addition to conventional physiotherapy)
Study: 33285037
Drug: Viltolarsen 40
Normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Viltolarsen 40 mg/kg/week
Study: 33285037
Drug: Viltolarsen 80
Normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Viltolarsen 80 mg/kg/week
Study: 33077839
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (ACT) after radical nephroureterectomy (RNU)
Study: 32212282
Drug: RWE for
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWE for older drugs
Study: 35018094
Drug: N‐AbA 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐AbA 300 mg
Study: 35018094
Drug: R‐AbA 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐AbA 1000 mg
Study: 32464936
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (DA)
Study: 35689208
Drug: Remimazolam tosilate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosilate (RT) 0.15 mg/kg with supplemental doses of 0.05 mg/kg as needed
Study: 35689208
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg with supplemental doses of 0.5 mg/kg
Study: 34544853
Drug: 20 extra
Normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at 2 to 3 months after stroke (subacute group)
Study: 34544853
Drug: 20 extra
Normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at ?30 days after stroke (acute group)
Study: 34544853
Drug: 20 extra
Normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at ?6 months after stroke (chronic group)
Study: 35108059
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months)
Study: 34649223
Drug: Remdesivir (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30‐60 minutes) in addition to standard care
Study: 36396600
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual daily activities for 8 weeks)
Study: 36038172
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 bolus (180,000 IU) maintained by daily dose of 2000 IU
Study: 36038172
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (40 mg daily)
Study: 35217796
Drug: Psilocybin 15
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 15 mg
Study: 35217796
Drug: Psilocybin 30
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin 30 mg
Study: 35217796
Drug: LSD (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (both doses)
Study: 616788766
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy with Jasmine oil
Study: 616788766
Drug: Aroma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aroma therapy with Jasmine oil
Study: 36109691
Drug: Droperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1 mg) + Dexamethasone (5 mg)
Study: 36109691
Drug: Tropisetron (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (5 mg) + Dexamethasone (5 mg)
Study: 36109691
Drug: Dexamethasone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (5 mg) + Saline (5 ml)
Study: 33069871
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment only
Study: 35105186
Drug: LSD (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (50 μg)
Study: 33295851
Drug: Curcumin-galactomannan (CGM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin-galactomannan (CGM) 500 mg twice daily for 30 days
Study: 35732486
Drug: Multifaceted quality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted quality improvement intervention including monthly feedback, interactive education, action toolbox, and bimonthly surveys.
Study: 33863775
Drug: Neonatal hyperglycaemia
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal hyperglycaemia >8 mmol/L
Study: 33863775
Drug: Neonatal hyperglycaemia
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal hyperglycaemia >8 mmol/L for 3 consecutive days
Study: 34586459
Drug: Levilimab (LVL)
Normalized name: elapegademase-lvlr
DrugBank: Levilimab (DB16387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levilimab (LVL) 324 mg
Study: 32066497
Drug: 1 g/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/8 h by continuous infusion (CI)